

Ivermectin 1% cream (Soolantra[®]) for the treatment of inflammatory lesions of papulopustular rosacea

NHS Devon

Commissioning policy

The routine commissioning of ivermectin 1% cream (Soolantra[®]) is accepted in Devon for the treatment of inflammatory lesions of moderate to severe papulopustular rosacea (PPR).

The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Ivermectin 1% cream offers patients an additional option in the topical treatment of papulopustular rosacea (PPR). In clinical trials, ivermectin has shown greater clinical efficacy than both vehicle cream and topical metronidazole in the treatment of inflammatory lesions of moderate to severe PPR. Adverse event profiles were similar to other topical agents. The acquisition cost of a 4-month course ivermectin cream is lower than the average cost of treatments currently used and is considered to offer value for money.

Guidance notes on exceptionality

Not applicable.

Date of publication:	Version:
29.11.2016	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG Policy adopted by NHS Devon CCG on 01.04.2019 Policy adopted by NHS Devon ICB on 01.07.2022